GEO series
Gene expression and mutation profiles in advanced-stage epithelial ovarian cancer (EOC)
GSE284400
Homo sapiens
Expression profiling by high throughput sequencing; Other
78 samples
Submitted 2025/01/15
Platform GPL16791
Summary
Purpose: This open-label, investigator-initiated, phase II study was conducted to evaluate the safety, survival and neoadjuvant outcomes of NAC combined with dual immune checkpoint inhibitors in advanced-stage EOC. Patients and methods: Between June 2019 and July 2021, 45 patients with unresectable stage III-IV EOC were enrolled. The patients received three cycles of NAC combined with durvalumab and tremelimumab. All patients underwent interval debulking surgery and received three cycles of durvalumab and adjuvant chemotherapy, followed by 12 cycles of durvalumab as maintenance therapy. The primary endpoint was the 12-month progression-free survival (PFS) rate; the secondary endpoints were the objective response rate (ORR) after NAC, a chemotherapy response score (CRS), pathologic complete response (pCR), overall survival (OS), and safety. The pre-planned exploratory analyses assessed the lymphocyte infiltration, PD-L1 expression, and genomic profiles of pre-treatment tumors.
Published in
Park J, Joung JG, Lim MC et al.
· Clinical cancer research : an official journal of the American Association for Cancer Research 2025
· PMID 40043003
· doi:10.1158/1078-0432.CCR-24-3753
This dataset
Download
Direct links to NCBI, no account and no request form: the whole study as GSE284400_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 78 samples. Raw sequencing reads are also available from ENA.
Also filed as BioProject PRJNA1198945. Searching any of these in the dataset finder brings you back here.
Study design
40 conditions, each sampled once — no replicated groups
Read from the first 40 of 78 sample titles: 40 distinct titles with little repetition. Check it against the sample list below before relying on it.
Samples in this study
0 selected
- GSM8683349 EOC004_RNAseq
- GSM8683350 EOC005_RNAseq
- GSM8683351 EOC006_RNAseq
- GSM8683352 EOC007_RNAseq
- GSM8683353 EOC008_RNAseq
- GSM8683354 EOC009_RNAseq
- GSM8683355 EOC010_RNAseq
- GSM8683356 EOC011_RNAseq
- GSM8683357 EOC012_RNAseq
- GSM8683358 EOC013_RNAseq
- GSM8683359 EOC014_RNAseq
- GSM8683360 EOC015_RNAseq
- GSM8683361 EOC016_RNAseq
- GSM8683362 EOC017_RNAseq
- GSM8683363 EOC018_RNAseq
- GSM8683364 EOC019_RNAseq
- GSM8683365 EOC020_RNAseq
- GSM8683366 EOC021_RNAseq
- GSM8683367 EOC022_RNAseq
- GSM8683368 EOC024_RNAseq
- GSM8683369 EOC025_RNAseq
- GSM8683370 EOC027_RNAseq
- GSM8683371 EOC028_RNAseq
- GSM8683372 EOC029_RNAseq
- GSM8683373 EOC030_RNAseq
- GSM8683374 EOC031_RNAseq
- GSM8683375 EOC032_RNAseq
- GSM8683376 EOC033_RNAseq
- GSM8683377 EOC034_RNAseq
- GSM8683378 EOC035_RNAseq
- GSM8683379 EOC036_RNAseq
- GSM8683380 EOC037_RNAseq
- GSM8683381 EOC038_RNAseq
- GSM8683382 EOC039_RNAseq
- GSM8683383 EOC040_RNAseq
- GSM8683384 EOC041_RNAseq
- GSM8683385 EOC042_RNAseq
- GSM8683386 EOC001_WES
- GSM8683387 EOC002_WES
- GSM8683388 EOC003_WES
+ 38 more — browse all 78 samples with per-sample file links →
Similar datasets
- GSE281556 Lysosomal sequestration of PARP inhibitors drives heterogeneous accumulation in ovarian cancer to increase efficacy 204 samples
- GSE317605 A Phase II Trial of Pembrolizumab plus Granulocyte Macrophage Colony Stimulating Factor in Advanced Biliary Cancer [CITE-Seq] 168 samples
- GSE270387 Single cell profiling of peripheral blood mononuclear cells in diverse men with prostate cancer reveals lethal disease-associated immune signatures 165 samples
- GSE336781 ZFP36L2 orchestrates stress-adaptive plasticity in intestinal regeneration and colorectal cancer metastasis 93 samples
- GSE235715 Multi-scaled transcriptomics of chronically inflamed nasal epithelium reveals immune-epithelial dynamics and tissue remodeling in nasal polyp formation 60 samples
- GSE234654 DDX6 reshapes the cancer RNA editome to suppress RNA-induced innate immunity 57 samples
- GSE335494 B-cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma 44 samples
- GSE272348 Late-stage tertiary lymphoid structures in hepatocellular carcinoma treated with neoadjuvant immune checkpoint blockade 31 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.